Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018

Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018”. The report is an essential source of information and analysis on the global Unstable Angina Therapeutics market. The report identifies the key trends shaping and driving the global Unstable Angina Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Unstable Angina Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Unstable Angina Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Unstable Angina Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Unstable Angina Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Unstable Angina Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Unstable Angina Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Unstable Angina Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Unstable Angina Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Unstable Angina Therapeutics market landscape? – Identify, understand and capitalize. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Unstable Angina Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Etiology of Unstable Angina
2.3.2 Pathophysiology of Unstable Angina
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.7 Lifestyle Changes
2.8 Medical Treatment
2.8.1 Medical Procedures
2.8.2 Cardiac Rehabilitation
2.9 GlobalData Pipeline Report Guidance
3 Unstable Angina Therapeutics - Market Characterization
3.1 Unstable Angina Therapeutics Market Size (2005-2010) - Global
3.2 Unstable Angina Therapeutics Market Forecast (2010-2018) - Global
3.3 Unstable Angina Therapeutics Market Size (2005-2010) - the US
3.4 Unstable Angina Therapeutics Market Forecast (2010-2018) - the US
3.5 Unstable Angina Therapeutics Market Size (2005-2010) - France
3.6 Unstable Angina Therapeutics Market Forecast (2010-2018) - France
3.7 Unstable Angina Therapeutics Market Size (2005-2010) - Germany
3.8 Unstable Angina Therapeutics Market Forecast (2010-2018) - Germany
3.9 Unstable Angina Therapeutics Market Size (2005-2010) - Italy
3.10 Unstable Angina Therapeutics Market Forecast (2010-2018) - Italy
3.11 Unstable Angina Therapeutics Market Size (2005-2010) - Spain
3.12 Unstable Angina Therapeutics Market Forecast (2010-2018) - Spain
3.13 Unstable Angina Therapeutics Market Size (2005-2010) - the UK
3.14 Unstable Angina Therapeutics Market Forecast (2010-2018) - the UK
3.15 Unstable Angina Therapeutics Market Size (2005-2010) - Japan
3.16 Unstable Angina Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Unstable Angina Therapeutics Market
3.17.1 Drivers for the Unstable Angina Therapeutics Market
3.17.2 Barriers for the Unstable Angina Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Unstable Angina Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Marketed Products Profiles for the Unstable Angina Therapeutics Market
4.3.1 Low Molecular Weight Heparins
4.3.2 Glycoprotein IIb/IIIa Inhibitor
4.3.3 Sodium Channel Current Inhibitor
4.3.4 Nitrates
4.3.5 Beta-adrenergic Receptor Blockers (Beta Blockers)
4.3.6 Calcium Channel Blockers
4.3.7 Angiotensin Converting Enzyme Inhibitor
4.3.8 Statins
4.3.9 Selective If Channel Inhibitor
4.4 Key Takeaway
5 Unstable Angina Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Unstable Angina Therapeutics - Pipeline Analysis by Clinical Phase of Development
5.3.1 Unstable Angina Therapeutics - Phase III Clinical Pipeline
5.3.2 Unstable Angina Therapeutics - Phase II Clinical Pipeline
5.3.3 Unstable Angina Therapeutics - Phase I Clinical Pipeline
5.3.4 Unstable Angina Therapeutics - Preclinical Phase Pipeline
5.4 Unstable Angina Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Unstable Angina Therapeutics - Most Promising Drugs in Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 Rivaroxaban
5.7.2 Otamixaban
5.7.3 A-002 (Varespladib Methyl)
5.8 Key Takeaway
6 Unstable Angina Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Sponsors
6.6 Top Companies Participating in Unstable Angina Therapeutics Clinical Trials
7 Unstable Angina Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Unstable Angina Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Anthera Pharmaceuticals
8.2.2 Bayer HealthCare
8.2.3 Sanofi
8.2.4 Ablynx
8.2.5 Cytokinetics
8.3 Other Companies in the Unstable Angina Therapeutics Market
8.4 Key Takeaway
9 Unstable Angina Therapeutics - Licensing & Partnership Deals
10 Unstable Angina Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Canadian Cardiovascular Society Grading of Angina Pectoris
Table 2: Unstable Angina Prevalence in Seven Major Markets
Table 3: Unstable Angina Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: Unstable Angina Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 5: Unstable Angina Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 6: Unstable Angina Therapeutics Market, the US, Forecast ($m), 2010-2018
Table 7: Unstable Angina Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: Unstable Angina Therapeutics Market, France, Forecast ($m), 2010-2018
Table 9: Unstable Angina Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: Unstable Angina Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 11: Unstable Angina Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: Unstable Angina Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 13: Unstable Angina Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: Unstable Angina Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 15: Unstable Angina Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 16: Unstable Angina Therapeutics Market, the UK, Forecast ($m), 2010-2018
Table 17: Unstable Angina Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: Unstable Angina Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 19: Comparison of Major Marketed Products in the Unstable Angina Therapeutics Market, 2011
Table 20: Unstable Angina Therapeutics Market, Phase III and Regulatory Filed Pipeline, 2011
Table 21: Unstable Angina Therapeutics Market, Phase II Pipeline, 2011
Table 22: Unstable Angina Therapeutics Market, Phase I Pipeline, 2011
Table 23: Unstable Angina Therapeutics Market, Pre-clinical and Discovery Phase Pipeline, 2011
Table 24: Unstable Angina Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011
Table 25: Unstable Angina Therapeutics, Global, Clinical Trials, 2011
Table 26: Unstable Angina Therapeutics, Global, Clinical Trials by Phase, 2011
Table 27: Unstable Angina Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 28: Unstable Angina Therapeutics, Global, Prominent Sponsors, 2011
Table 29: Unstable Angina Therapeutics, Global, Overall Sponsors, 2011
Table 30: Unstable Angina Therapeutics, Global, Top Five Companies by Phase, 2011
Table 31: Anthera Pharmaceuticals - Unstable Angina, Pipeline, 2011
Table 32: Bayer HealthCare - Unstable Angina, Pipeline, 2011
Table 33: Sanofi - Unstable Angina, Pipeline, 2011
Table 34: Ablynx - Unstable Angina, Pipeline, 2011
Table 35: Cytokinetics - Unstable Angina, Pipeline, 2011
Table 36: Other Companies in the Unstable Angina Therapeutics Market
Table 37: Unstable Angina Therapeutics, Global, Deals - 2011

1.2 List of Figures
Figure 1: Graphic Presentation of Unstable Angina
Figure 2: Impact of Atherosclerosis on Arteries
Figure 3: Progression of Coronary Artery Disease (CAD)
Figure 4: Unstable Angina Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 5: Unstable Angina Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 6: Unstable Angina Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 7: Unstable Angina Therapeutics Market, the US, Forecast ($m), 2010-2018
Figure 8: Unstable Angina Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: Unstable Angina Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 10: Unstable Angina Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: Unstable Angina Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 12: Unstable Angina Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: Unstable Angina Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 14: Unstable Angina Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: Unstable Angina Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 16: Unstable Angina Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 17: Unstable Angina Therapeutics Market, the UK, Forecast ($m), 2010-2018
Figure 18: Unstable Angina Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 19: Unstable Angina Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 20: Opportunity and Unmet Need in the Unstable Angina Therapeutics Market
Figure 21: Strategic Competitor Assessment of the Marketed Products in Unstable Angina Therapeutics, 2011
Figure 22: Unstable Angina Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 23: Unstable Angina Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011
Figure 24: Technology Trends Analytics Framework, 2011
Figure 25: Technology Trends Analytics Frame Work - Description, 2011
Figure 26: Unstable Angina Therapeutics, Global, Clinical Trials by Country, 2011
Figure 27: Unstable Angina Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 28: Unstable Angina Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 29: Unstable Angina Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 30: Unstable Angina Therapeutics, Global, Overall Sponsors (%), 2011
Figure 31: Unstable Angina Therapeutics, Global, Top Five Companies by Phase, 2011
Figure 32: Unstable Angina Therapeutics Market, Drivers and Restraints, 2011
Figure 33: Implications for Future Market Competition in the Unstable Angina Therapeutics Market, 2011
Figure 34: Unstable Angina Therapeutics Market, Global, Future Players, 2011
Figure 35: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018”. The report is an essential source of information and analysis on the global unstable angina therapeutics market. The report identifies the key trends shaping and driving the global unstable angina therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global unstable angina therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Unstable Angina Therapeutics Market Expected to Show Slow Growth until 2018

GlobalData has estimated the global unstable angina therapeutics market to be worth $2,834.0m in 2010. It is expected to grow to $3,139.1m with a Compound Annual Growth Rate (CAGR) of 1.3% by 2018. This slow growth can be primarily attributed to the rise in the number of patients undergoing treatment for unstable angina and the expected approval of novel therapies such as rivaroxaban, varespladib and otamixaban, which are currently in the late stage of clinical development. However, if approved, these products are expected to be marketed at a premium price compared to other treatment options for unstable angina. The launch of products at premium prices is attributed to the novel mechanism of action of these products leading to a marked improvement in efficacy and safety over the currently marketed products. Therefore the market penetration of these products is expected to remain low in a generics dominated market, limiting the growth rate of the unstable angina therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in European countries, and Crestor (rosuvastatin) in 2016. The patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the unstable angina therapeutics market is expected to witness slow growth with numerous generics playing a major role in the forecast period; this is similar to the present market scenario.

Anthera Pharmaceuticals
Bayer HealthCare
Sanofi
Ablynx
Cytokinetics